PXS-4787
PXS-4787 is a specific and effective pan-LOX (lysyl oxidase) inhibitor for abolishing lysyl oxidase activity. PXS-4787 inhibits LOX with IC50s of 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), 0.2 μM (rh LOXL4), respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2409963-50-2
- Formule: C10H12FNO2S
- Masse moléculaire:229.27
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), 0.2 μM (rh LOXL4)[1]
Lysyl oxidases stabilize the main component of scar tissue, collagen, and drive scar stiffness and appearance[1].
PXS-4787 (0-10 μM; 15 min-4 h) dose- and time-dependently inhibits lysyl oxidase and displays comparable inhibitory activity across species[1].
PXS-4787 (0-100 μM; 72 h) is well tolerated by primary human dermal fibroblasts, (10 μM; 11 d) reduces collagen formation, deposition and crosslinking in primary human dermal fibroblasts cultured in vitro[1].
PXS-4787 (10 μM; 48 h) induces differential gene expression in fibroblasts and keratinocytes, including COL1A1, LOX, GAPDH, PGK1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary human dermal fibroblasts cultured in vitro
-
Concentration:0, 1, 10 μM
-
Incubation Time:11 days
-
Result:Significantly reduced in the 10 µM treatment group.
-
Cell Line:Cultured fibroblasts and keratinocytes (isolated from five different patients)
-
Concentration:10 μM
-
Incubation Time:48 hours
-
Result:Resulted four genes with significant differential expression in fibroblasts and two differentially expressed genes in keratinocytes.
PXS-4787 (3%, oil in water cream; external application; once daily, for 12 weeks) also significantly improves scar appearance without reducing tissue strength in porcine injury models under topical application[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Porcine excision injury model (female Juvenile pigs, 18-20 kg)[1]
-
Dosage:3%, oil in water cream; 400 mg cream applied to 16 cm2
-
Administration:External application; 1, 2 and 3 weeks post-injury; once dailly, for 12 weeks
-
Result:Improved the appearance of scar in relevant in vivo models, indicative of a targetdriven, as opposed to compound-specific, effect.
Chemical Information
-
CAS No. 2409963-50-2
-
Masse moléculaire 229.27
-
Formule C10H12FNO2S
-
SMILES
NC/C=C(CS(=O)(C1=CC=CC=C1)=O)\F
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvant et solubilité
DMSO : 25 mg/mL (109.04 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
Références
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3617 mL | 21.8083 mL | 43.6167 mL | 109.0417 mL |
| 5 mM | 0.8723 mL | 4.3617 mL | 8.7233 mL | 21.8083 mL | |
| 10 mM | 0.4362 mL | 2.1808 mL | 4.3617 mL | 10.9042 mL | |
| 15 mM | 0.2908 mL | 1.4539 mL | 2.9078 mL | 7.2694 mL | |
| 20 mM | 0.2181 mL | 1.0904 mL | 2.1808 mL | 5.4521 mL | |
| 25 mM | 0.1745 mL | 0.8723 mL | 1.7447 mL | 4.3617 mL | |
| 30 mM | 0.1454 mL | 0.7269 mL | 1.4539 mL | 3.6347 mL | |
| 40 mM | 0.1090 mL | 0.5452 mL | 1.0904 mL | 2.7260 mL | |
| 50 mM | 0.0872 mL | 0.4362 mL | 0.8723 mL | 2.1808 mL | |
| 60 mM | 0.0727 mL | 0.3635 mL | 0.7269 mL | 1.8174 mL | |
| 80 mM | 0.0545 mL | 0.2726 mL | 0.5452 mL | 1.3630 mL | |
| 100 mM | 0.0436 mL | 0.2181 mL | 0.4362 mL | 1.0904 mL |